Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Lindner

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Plos One|August 24, 2012
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivoAaron Petty, Eugene Myshkin, Haina Qin, et al.
Molecular Cancer Therapeutics|August 15, 2014
Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancerMelissa A Babcook, Sanjeev Shukla, Pingfu Fu, et al.
Bioconjugate Chemistry|January 19, 2006
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis modelDarren P Baker, Edward Y Lin, Kochung Lin, et al.
Cancer Research|May 20, 2016
Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple MyelomaSergei Vatolin, James G Phillips, Babal K Jha, et al.
Molecular Cancer|May 28, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
Research Square|May 4, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
Cancers|June 2, 2021
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple MyelomaMetis Hasipek, Dale Grabowski, Yihong Guan, et al.
Cancer Research|January 13, 2023
KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder CancerHong Qiu, Vladimir Makarov, Jennifer K Bolzenius, et al.
Leukemia|June 27, 2022
Rare germline alterations of myeloperoxidase predispose to myeloid neoplasmsSunisa Kongkiatkamon, Laila Terkawi, Yihong Guan, et al.
Blood Cancer Discovery|March 8, 2021
A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid NeoplasmsYihong Guan, Anand D Tiwari, James G Phillips, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Plos One|August 24, 2012
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivoAaron Petty, Eugene Myshkin, Haina Qin, et al.
Molecular Cancer Therapeutics|August 15, 2014
Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancerMelissa A Babcook, Sanjeev Shukla, Pingfu Fu, et al.
Bioconjugate Chemistry|January 19, 2006
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis modelDarren P Baker, Edward Y Lin, Kochung Lin, et al.
Cancer Research|May 20, 2016
Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple MyelomaSergei Vatolin, James G Phillips, Babal K Jha, et al.
Molecular Cancer|May 28, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
Research Square|May 4, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
Cancers|June 2, 2021
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple MyelomaMetis Hasipek, Dale Grabowski, Yihong Guan, et al.
Cancer Research|January 13, 2023
KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder CancerHong Qiu, Vladimir Makarov, Jennifer K Bolzenius, et al.
Leukemia|June 27, 2022
Rare germline alterations of myeloperoxidase predispose to myeloid neoplasmsSunisa Kongkiatkamon, Laila Terkawi, Yihong Guan, et al.
Blood Cancer Discovery|March 8, 2021
A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid NeoplasmsYihong Guan, Anand D Tiwari, James G Phillips, et al.
Pageof 8